High-throughput discovery of antibodies for hard-to-study membrane proteins
Official title: High-throughput Discovery of Antibodies against Understudied Membrane Proteins using mRNA
Funded at Integral Molecular · NIH-11394660 · Data updated 2026-11-12
A NIH grant aims to create and test many monoclonal antibodies against important but understudied membrane proteins to help research and potential therapies.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Integral Molecular NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $631,033 |
| NIH project number | 5R44GM150317-03 |
| Project ID | NIH-11394660 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable as a direct patient study; the work relates to foundational reagent development used by researchers and clinicians.
✕Less likely to help
There is no direct patient intervention; the grant focuses on reagent development.
What this research studies
This project focuses on developing a high-throughput method to generate antibodies that recognize GPCRs and ion channels on living cells. By overcoming traditional hurdles in expressing these membrane proteins, the effort seeks to produce reagents that can advance research, diagnostics, and potential treatments. Researchers will leverage innovative antibody discovery approaches to identify MAbs that bind native proteins on cell surfaces.
Why it matters
Potential benefit: If successful, patients could benefit from better research tools that accelerate drug discovery and diagnostic testing for diseases linked to these targets.
How similar studies have gone: Previous IDG efforts have advanced many antibody reagents, showing that high-throughput approaches can yield useful antibodies for difficult targets.
Where this research is happening
-
Integral Molecular
Philadelphia, United States Active
Researchers
- Principal investigator: Chambers, Ross S — Integral Molecular
- Study coordinator: Chambers, Ross S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.